Get the Stockscreener App
18.11
0.21%
0.0486
Zymeworks Inc. stock is traded at $18.11, with a volume of 227.69K.
It is up +0.21% in the last 24 hours and up +14.98% over the past month.
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
See More
Previous Close:
$18.06
Open:
$18.1
24h Volume:
227.69K
Relative Volume:
0.45
Market Cap:
$1.36B
Revenue:
$62.71M
Net Income/Loss:
$-112.51M
P/E Ratio:
-11.99
EPS:
-1.51
Net Cash Flow:
$-96.01M
1W Performance:
+8.47%
1M Performance:
+14.98%
6M Performance:
+70.25%
1Y Performance:
+37.10%
1-Day Range:
$17.73
$18.49
1-Week Range:
$16.20
$18.49
52-Week Range:
$9.03
$18.49
Zymeworks Inc. Stock (ZYME) Company Profile
Name
Zymeworks Inc.
Sector
Industry
Phone
604-678-1388
Address
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
18.13 | 1.37B | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.64 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.68 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.46 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.32 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.07 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | TD Cowen | Buy |
| Dec-16-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-07-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-01-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-21-23 | Resumed | Wells Fargo | Overweight |
| Jan-04-23 | Reiterated | H.C. Wainwright | Neutral |
| Dec-20-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-04-22 | Resumed | Wells Fargo | Overweight |
| May-05-22 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-15-22 | Initiated | Evercore ISI | Outperform |
| Dec-10-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-17-21 | Resumed | Guggenheim | Neutral |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Feb-25-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-08-21 | Resumed | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Aug-06-20 | Initiated | SVB Leerink | Outperform |
| Jan-10-20 | Initiated | Wolfe Research | Outperform |
| Dec-09-19 | Initiated | JP Morgan | Neutral |
| Nov-25-19 | Initiated | H.C. Wainwright | Buy |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-30-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-30-19 | Initiated | Stifel | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| May-11-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-19-18 | Initiated | Raymond James | Outperform |
View All
Zymeworks Inc. Stock (ZYME) Latest News
Applying Elliott Wave Theory to Zymeworks Inc.Breakout Watch & Comprehensive Market Scan Reports - newser.com
Using economic indicators to assess Zymeworks Inc. potentialOptions Play & Community Consensus Picks - newser.com
What the charts say about Zymeworks Inc. todayCPI Data & Reliable Breakout Forecasts - newser.com
What technical models suggest about Zymeworks Inc.’s comebackQuarterly Performance Summary & Precise Swing Trade Alerts - newser.com
Will Zymeworks Inc. stock outperform growth indexesMarket Movers & Low Drawdown Momentum Ideas - newser.com
How Zymeworks Inc. stock compares to market leadersSwing Trade & Fast Momentum Stock Entry Tips - newser.com
Is Zymeworks Inc. showing signs of accumulationForecast Cut & Short-Term Trading Alerts - newser.com
Will Zymeworks’ (ZYME) New R&D Leadership Mark a Turning Point in Its Oncology Strategy? - Yahoo
Zymeworks (NYSE:ZYME) Stock Price Up 7.2%Here's What Happened - MarketBeat
Zymeworks (NASDAQ:ZYME) Reaches New 52-Week HighHere's Why - MarketBeat
Zymeworks stock hits 52-week high at 17.71 USD By Investing.com - Investing.com Canada
How Might ZYME’s Shifting Leadership Shape Its Late-Stage Oncology Ambitions? - simplywall.st
B. Riley Securities Initiates Coverage of Zymeworks (ZYME) with Buy Recommendation - Nasdaq
Zymeworks stock hits 52-week high at 17.71 USD - Investing.com
Zymeworks (ZYME) Coverage Initiated by B. Riley Securities with 'Buy' Rating | ZYME Stock News - GuruFocus
Lifesci Capital Forecasts Zymeworks' Q3 Earnings (NYSE:ZYME) - MarketBeat
Zymeworks appoints Adam Schayowitz as acting chief development officer By Investing.com - Investing.com Nigeria
Zymeworks Appoints New Acting Chief Development Officer to Boost Therapeutic Advancements - TipRanks
Zymeworks appoints Adam Schayowitz as acting chief development officer - Investing.com India
Zymeworks Inc. Appoints Adam Schayowitz, Ph.D., MBA as Acting Chief Development Officer - Quiver Quantitative
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer - Stock Titan
Q1 Earnings Forecast for Zymeworks Issued By Lifesci Capital - MarketBeat
How to forecast Zymeworks Inc. trends using time series2025 Dividend Review & Community Consensus Trade Alerts - newser.com
Is Zymeworks Inc a good long term investmentShort-Term Trading Alerts & Small Capital Trading Plans - earlytimes.in
Is Zymeworks Inc. stock entering bullish territoryPortfolio Risk Report & Free Fast Gain Swing Trade Alerts - newser.com
Why analysts maintain buy rating on Zymeworks Inc. (ZA8) stockJuly 2025 Patterns & Precise Swing Trade Entry Alerts - newser.com
Market reaction to Zymeworks Inc.’s recent news2025 Dividend Review & Technical Buy Zone Confirmation - newser.com
Key resistance and support levels for Zymeworks Inc.Quarterly Portfolio Review & Reliable Entry Point Alerts - newser.com
Zymeworks (ZYME): Assessing Valuation Following Recent Momentum in Biopharma - Sahm
Will Zymeworks Inc. stock outperform tech sector in 2025July 2025 Analyst Calls & Scalable Portfolio Growth Ideas - newser.com
Will Zymeworks Inc. stock recover faster than peersQuarterly Profit Summary & Daily Volume Surge Signals - newser.com
How Zymeworks Inc. (ZA8) stock stacks up against competitorsJuly 2025 Fed Impact & Fast Gain Swing Trade Alerts - newser.com
Zymeworks Inc Stock Analysis and ForecastMACD Histogram Signals & Get Tomorrow’s Winners Today With AI - earlytimes.in
Platinum Investment Management Ltd. Decreases Stake in Zymeworks Inc. $ZYME - MarketBeat
What indicators show strength in Zymeworks Inc.Trade Entry Summary & Weekly Watchlist of Top Performers - newser.com
Voya Investment Management LLC Sells 43,861 Shares of Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Inc. Stock (ZYME) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zymeworks Inc. Stock (ZYME) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | Director |
May 19 '25 |
Buy |
11.78 |
5,919 |
69,738 |
17,883,908 |
| EcoR1 Capital, LLC | Director |
Apr 16 '25 |
Buy |
11.16 |
73,953 |
825,589 |
17,773,727 |
| EcoR1 Capital, LLC | Director |
Apr 17 '25 |
Buy |
11.52 |
54,760 |
630,819 |
17,828,487 |
| EcoR1 Capital, LLC | Director |
Apr 04 '25 |
Buy |
11.17 |
196,438 |
2,193,800 |
17,699,774 |
| EcoR1 Capital, LLC | Director |
Apr 03 '25 |
Buy |
11.84 |
120,770 |
1,430,170 |
17,503,336 |
| EcoR1 Capital, LLC | Director |
Apr 02 '25 |
Buy |
11.85 |
74,360 |
881,017 |
17,382,566 |
| EcoR1 Capital, LLC | Director |
Apr 01 '25 |
Buy |
11.60 |
48,658 |
564,647 |
17,308,206 |
| EcoR1 Capital, LLC | Director |
Mar 31 '25 |
Buy |
11.75 |
4,397 |
51,658 |
17,259,548 |
| EcoR1 Capital, LLC | Director |
Mar 25 '25 |
Buy |
12.91 |
53,501 |
690,452 |
17,211,303 |
| EcoR1 Capital, LLC | Director |
Mar 26 '25 |
Buy |
12.24 |
43,848 |
536,857 |
17,255,151 |
1.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):